All rights reserved. No reuse allowed without permission.

# Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients

4

Tesa M. Severson<sup>1,2,3,\*</sup>, Yanyun Zhu<sup>1,2,\*</sup>, Stefan Prekovic<sup>1,2,\*</sup>, Karianne Schuurman<sup>1</sup>, Holly M.
Nguyen<sup>4</sup>, Lisha G. Brown<sup>4</sup>, Sini Hakkola<sup>5</sup>, Yongsoo Kim<sup>1,6</sup>, Jeroen Kneppers<sup>1,2</sup>, Simon Linder<sup>1,2</sup>, Suzan Stelloo<sup>1,2,7</sup>, Cor Lieftink<sup>3</sup>, Michiel van der Heijden<sup>3,8</sup>, Matti Nykter<sup>5</sup>, Vincent van der Noort<sup>9</sup>, Joyce Sanders<sup>10</sup>, Ben Morris<sup>3</sup>, Guido Jenster<sup>11</sup>, Geert JLH van Leenders<sup>12</sup>, Mark Pomerantz<sup>13</sup>, Matthew L. Freedman<sup>13,14</sup>, Roderick L. Beijersbergen<sup>3</sup>, Alfonso Urbanucci<sup>5,15</sup>, Lodewyk Wessels<sup>2,3,16</sup>, Eva Corey<sup>4</sup>, Wilbert Zwart<sup>1,2,17#</sup>, Andries M. Bergman<sup>1,8#</sup>

- 12
- 13 **1** Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 14 **2** Oncode Institute, Utrecht, the Netherlands
- 15 **3** Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the
- 16 Netherlands
- 17 4 Department of Urology, University of Washington, Seattle, WA, USA
- 5 Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere
   University and Tays Cancer Centre, Tampere, Finland
- 20 6 present working address: Department of Pathology, Cancer Center Amsterdam,
   21 Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
- 22 **7** present working address: Department of Molecular Biology, Faculty of Science, Radboud
- 23 Institute for Molecular Life Sciences, Oncode Institute, Radboud University, Nijmegen, 6525
- 24 GA Nijmegen, the Netherlands.
- 25 8 Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the
   26 Netherlands
- 27 9 Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 28 **10** Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
- 29 **11** Department of Urology, Erasmus MC, Rotterdam, the Netherlands
- 30 **12** Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre,
   31 Rotterdam, the Netherlands.
- **13** Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School,
   Boston, MA, USA.
- 34 14 The Eli and Edythe L. Broad Institute, Cambridge, MA, USA
- 15 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital,
   Oslo, Norway
- **16** Department of EEMCS, Delft University of Technology, Delft, the Netherlands.
- 38 **17** Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department
- 39 of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the
- 40 Netherlands.
- 41
- 42 \*shared first authors
- 43 # corresponding authors: <u>w.zwart@nki.nl</u>, a.bergman@nki.nl
- 44
- 45
- 46 **Keywords:** mCRPC, enzalutamide, epigenetics, androgen receptor H3K27ac, HDAC 47 inhibitors, biomarkers, hormone intervention

All rights reserved. No reuse allowed without permission.

48

#### 49 Abstract

Androgen Receptor (AR) signaling inhibitors, including enzalutamide, are treatment options 50 51 for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance 52 inevitably develops. Using metastatic samples from a prospective phase II clinical trial, we enhancer/promoter H3K27ac 53 epigenetically profiled activities with chromatin 54 immunoprecipitation followed by sequencing, before and after AR-targeted therapy. We identified a distinct subset of H3K27ac-differentially marked regions that associated with 55 56 treatment responsiveness. These data were successfully validated in mCRPC patient-57 derived xenograft models (PDX). In silico analyses revealed HDAC3 as a critical factor that 58 can drive resistance to hormonal interventions, which we validated in vitro. Using cell lines 59 and mCRPC PDX tumors in vitro, we identified drug-drug synergy between enzalutamide and 60 the pan-HDAC inhibitor vorinostat, providing therapeutic proof-of-concept. These findings demonstrate rationale for new therapeutic strategies using a combination of AR and HDAC 61 62 inhibitors to improve patient outcome in advanced stages of mCRPC.

- 63
- 64
- 65
- 66
- 67
- 68 69
- 70
- 71
- 72

All rights reserved. No reuse allowed without permission.

73

#### 74 Background

Prostate cancer is the most prevalent cancer type in men, with globally over 1.4 million new 75 76 diagnoses and 375,000 patients who succumb to the disease each year<sup>1</sup>. Although most 77 patients with high-risk localized disease are effectively treated with either prostatectomy or radiotherapy<sup>2</sup>, eventually 25% of patients will develop metastases for which there is currently 78 no cure<sup>3-5</sup>. Treatment of choice for metastatic prostate cancer patients is androgen 79 80 deprivation therapy (ADT) which reduces serum testosterone to castration levels, to which 81 virtually all patients initially respond. However, metastatic disease progression despite ongoing ADT, termed metastatic castration-resistant prostate cancer (mCRPC), is 82 83 inevitable<sup>6</sup>.

84

85 Androgen Receptor (AR) is a hormone-dependent transcription factor and the master 86 regulator of prostate cancer development and progression. Upon androgen stimulation, AR 87 alters its conformation, translocates into the nucleus<sup>7</sup> and associates to the chromatin at distal regulatory elements throughout the genome, hereafter referred to as its 'cistrome'. AR 88 chromatin binding is facilitated by pioneer factors, such as FOXA1<sup>8</sup>, and operates under tight 89 epigenetic control<sup>8,9</sup>. The majority of active AR sites are hallmarked by acetylation of lysine 90 residue 27 on histone 3 (H3K27ac), a marker of active enhancers and promoters<sup>10,11</sup>. Upon 91 92 formation of an active transcription complex, AR drives the expression of its target genes to control tumor cell growth. Following progression on ADT, further suppression of the AR 93 signaling axis by new generation AR inhibitors, such as enzalutamide, is an effective 94 treatment for mCRPC patients<sup>12,13</sup>. 95

97 Enzalutamide (ENZA) is a well-established therapy for the treatment of mCRPC. It 98 significantly decreases the risk of radiographic progression and death among mCRPC 99 patients in both the pre- and post-chemotherapy settings<sup>12,13</sup>. ENZA blocks AR signaling at 100 multiple levels, including diminished AR chromatin binding, and prevention of coregulator recruitment<sup>14</sup>. However, intrinsic resistance to ENZA is observed in up to 46% of mCRPC 101 patients and duration of response varies greatly between patients<sup>12,13</sup>. Consequently, 102 103 biomarkers for response prediction to AR-targeted therapeutics, including ENZA, are urgently 104 needed to identify those patients who may benefit from alternative treatment strategies. 105 Moreover, combination treatments to overcome or postpone resistance to AR-targeted 106 therapies, are urgently needed in the clinic.

107

Several studies have previously compared AR chromatin binding profiles in different disease stages and illustrated plasticity of AR cistromes in tumor development<sup>15,16</sup> and disease progression<sup>17,18</sup>, being predictive for outcome<sup>17</sup> and associated with treatment response in cell lines<sup>9</sup>. Despite our expanding knowledge of AR epigenetic alterations in prostate cancer patients and cell line models, there is limited knowledge on FOXA1 cistromics and H3K27ac profiles, in relation to drug resistance in mCRPC patients.

114

To identify the potential epigenetic alterations that drive ENZA response in mCRPC patients, metastasis-targeted biopsies were collected pre- and post- AR-targeting treatment, while response to treatment was monitored. Chromatin immunoprecipitation followed by massive parallel sequencing (ChIP-seq) was performed on all collected clinical specimens, charting the cistromes of H3K27ac, AR and FOXA1.

121 Comparative data analyses revealed a specific subset of 657 H3K27ac sites significantly enriched in metastatic lesions from mCRPC patients who did not respond to AR-targeted 122 treatment. These sites were associated with response to castration in mCRPC PDX models, 123 124 and regulate genes selectively expressed in ENZA-resistant cell line models, illustrating their potential to predict treatment response. Finally, we identified and functionally assessed 125 factors that selectively bind to these 657 resistance-associated H3K27ac sites in cell line 126 127 models, revealing novel therapeutic candidates and effective drug-drug combinations for treatment-resistant mCRPC patients. 128

129

#### 130 Methods

#### 131 Study design and participants

132 We conducted a single-arm, open-label, phase 2 study, in patients with mCRPC at the 133 Netherlands Cancer Institute. Male patients over 18 years of age, with histologically confirmed adenocarcinoma of the prostate, Eastern Cooperative Oncology Group (ECOG) 134 135 performance status 0-2, a serum testosterone level <50 ng/dl, scheduled for ENZA treatment and not previously treated with ENZA, with progressive disease, defined as a PSA rise 136 (PCWG3 criteria<sup>19</sup>) and/or radiographic progression (RECIST 1.1 criteria<sup>20</sup>) and metastatic 137 lesions of which a histological biopsy could safely be obtained, were included in the trial. This 138 139 single center cohort study was conducted as a sub-investigation of the CPCT-02 biopsy 140 protocol (NCT01855477), which aims to analyze the individual metastatic cancer genome in 141 patients, to develop future personal predictors for response to systemic treatment. Trial 142 procedures, treatment details, patient on-trial monitoring, definition of endpoints, sample size 143 calculations and statistical analysis, are included in the supplementary trial data (Supplementary Data). This study was approved by the local medical ethics committee of the 144 145 Netherlands Cancer Institute and was activated on January 24<sup>th</sup>, 2012. The protocol complied

with the ethical principles of the Declaration of Helsinki. Patients provided signed informed
 consent for translational studies and recording and analysis of baseline characteristics and
 clinical outcomes of ENZA treatment.

149

150 Tissue processing and chromatin immunoprecipitation analyses

151 Biopsies were taken from a lymph-node metastasis or visceral metastasis selected by CT scan, while sites for a biopsy from a bone metastasis were selected by <sup>68</sup>Ga-PSMA PET 152 153 scanning. Fresh-frozen metastatic biopsy samples from 64 CRPC patients was collected. 154 The tumor percentage of these samples was scored on hematoxylin and eosin (H&E) stained 155 slides by a dedicated pathologist. After tumor cell content was confirmed, chromatin 156 immunoprecipitations were performed for AR, FOXA1 and H3K27ac at qualified samples as 157 previously described<sup>21-23</sup>. In brief, lymph-node and visceral samples were cryo-sectioned into slices of 30µm, while bone samples were cryo-sectioned to slices of 10µm, and crosslinked 158 using DSG (20593; Thermo Fisher Scientific) for 25 min. For each sample, 5µg of antibody 159 and 50µl of either Protein A or Protein G magnetic beads (10008D or 10009D; Thermo Fisher 160 Scientific) were used. Inputs for individual patients were generated as controls. Antibodies 161 used were: AR (Millipore, 06-680), FOXA1 (Abcam, ab5089) and H3K27ac (Active motif, 162 163 39133). Libraries were prepared and sequenced using the Illumina HiSeg2500 (65 bp, single 164 end).

165

166 ChIP-seq data analysis

167 Raw sequence data were aligned to hg19 using BWA v0.5.20. Aligned reads were filtered for 168 mapping quality (MQ) > 20 using samtools v1.8<sup>24</sup>. Duplicate reads were marked using Picard 169 MarkDupes function v2.18 (http://broadinstitute.github.io/picard/). Peaks were called using 170 macs2 (v2.1.1)<sup>25</sup> with the fragment size determined using Phantompeakqualtools<sup>26</sup> against

171 corresponding input DNA for all samples. Phantompeakqualtools was used to identify the Relative Strand Cross-correlation (RSC)<sup>26</sup> and deepTools (v2.0)<sup>27</sup> to determine the fraction 172 of reads in peaks (FRiP) and readcounts. Samples with RSC > 0.7, FRiP  $\ge$  1.0 and  $\ge$  8,000 173 174 peaks were kept for further analysis (Supplementary Table 3). Snapshots of raw signal were generated using pyGenomeTracks (v3.6) with bigwig files<sup>28</sup>. Bigwig files were generated from 175 aligned bam files using deepTools v2.0 bamCoverage function. To correlate read count data 176 177 in 50kb bins across the genome for all samples and PDX samples, deepTools computeMatrix function was used on bigwigs followed by plotCorrelation. Visualization of raw reads was 178 179 carried out with bigwigs using deepTools (v2.0) computeMatrix, plotHeatmap and plotProfile 180 functions. visualizing profiles binding For of data between groups (non-181 responders/responders) at specific regions, aligned files from the samples within groups were 182 merged and subsequently downsampled to equivalent readcounts (~20 million reads) using 183 samtools and visualized using deepTools plotProfile. Principal component analysis was 184 carried out using plotPCA function with the reads counted in peaks (dba.count function) from 185 DiffBind package v2.4.8 in R v3.4.4. Supervised differential analyses using dba.analyze and resulting heatmap and volcano plot were generated using the DiffBind package (v2.4.8 in R 186 v3.4.4) with the reads counted in peaks using the dba.count function using default DESeg2 187 method. Volcano plot hexbin density tiles were plotted with R package hexbin (v1.28.1). 188 Genomic features were assigned to differential peaksets using ChIPSeeker (v1.26.2)<sup>29</sup> in R 189 190 (v4.0.3).

191

To compare H3K27ac signal across various samples in our non-responder H3K27ac regions
of interest, we first downloaded public PDX mCRPC H3K27ac ChIP-seq data<sup>18</sup> (GSE130408)
and additional H3K27ac data from primary prostate cancer patient tumors (e.g. Gleason 7,9,
cases, controls (GSE120738))<sup>30</sup> and aligned as above. In addition, we examined H3K27ac

data in the same manner from in-house generated datasets from treatment naïve metastatic samples, non-responder metastatic samples (this study), and publicly available healthy and primary tumor tissue (GSE130408)<sup>18</sup>. Visualizations of these data were generated with deepTools v2.0 computeMatrix followed by plotHeatmap of individual files and plotProfile as described above for binding data between groups.

201

For gene set enrichment, genes associated with H3K27ac non-responder sites (within 50kb of a transcription start site (TSS)) were identified in R (v4.0.3) using the ChIPSeeker package (v1.26.2)<sup>29</sup>. Enrichment tests for gene sets were performed in R (v4.1.2) using the GeneOverlap package (v1.30.0) and visualized in ggplot (v3.4.0). The average gene expression of these genes was calculated and plotted in public scRNA-seq from parental LNCaP cells and cells exposed to ENZA until resistance arose (RES-B<sup>31,32</sup>) using the Seurat package (v4.3.0)<sup>33</sup> in R (v4.1.2).

209

Readcounts and fraction of reads in peaks (FrIP) were visualized using the ggplot2 v2.3.3.0 with Wilcoxon tests performed with ggpubr package v0.3.0 in R v3.5.0. To determine significant enrichment of our intervals with publicly available ChIP-seq data we queried our intervals against the CistromeDB transcription factor dataset<sup>34</sup> using the GIGGLE search function<sup>35</sup>. Prostate and prostate cancer experiments (Supplemental Table 5) were selected specifically for analysis. A scatterplot of the mean Enrichment score (combo\_score) for each factor was generated using ggplot v2.3.3.0 in R v3.5.0 (Supplemental Table 5).

217

#### 218 Patient-derived xenograft studies

All animal experiments were performed after University of Washington IACUC approval
 following ARRIVE and NIH guidelines. Subcutaneous tumors were implanted in intact C.B.

221 17 SCID male mice (Charles River) and when tumors reached 100 mm<sup>3</sup> animals were randomized to control and castrated groups. Tumor growth and body weights were monitored 222 twice a week. Animals were sacrificed at the end of the study or when animals became 223 224 compromised. Responses to castration were also fully described previously<sup>36</sup>. The doubling 225 time was estimated using exponential (Malthusian) growth model. If only one value was available, doubling time was not computed. For samples with a negative doubling time, the 226 227 value was re-normalized to the mean value of the corresponding control model yielding a positive value. Significant differences between classes determined by one-way ANOVA 228 229 followed by post-hoc Tukey HSD test. Visualization was carried out in R using ggplot (v3.3.6)

230

#### 231 Cell lines and culture conditions

Castration-resistant prostate cancer models (LNCaP-Abl and LNCaP-16D<sup>37</sup>) were kindly provided by Helmut Klocker<sup>38</sup> and Amina Zoubeidi<sup>39</sup>. ENZA resistant LNCaP derivatives LNCaP-Enz<sup>R</sup> were kindly provided by the Donald Vander Griend<sup>40</sup>. LNCaP-Abl cells were cultured in RPMI-1640 medium containing 10% DCC (hormone deprived FBS), LNCaP-16D<sup>37</sup> cells were cultured in RPMI-1640 medium supplemented with 10% FBS, and LNCaP-Enz<sup>R</sup> cells were cultured in RPMI-1640 medium containing 10% FBS and 10µM ENZA. All cell lines were authenticated and tested for mycoplasma contamination.

239

#### siRNA screen proliferation assay and analyses

siRNAs were purchased from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA and
siPLK1 were applied as positive and negative controls. 5µl of 50nM siRNA pools were seeded
in individual wells of a 96 well-plate. Cells were reverse transfected with 5µl 1% Lipofectamine
RNAiMAX Reagent (Invitrogen, Eindhoven, Netherlands) in Optimem (Thermofisher,
Eindhoven, Netherlands) in 90µl culture medium. For LNCaP-Abl and LNCaP-16D, 10.000

cells were seeded per well, and 20.000 cells for LNCaP-Enz<sup>R</sup> cells. Optimal experimental setup was determined for each cell line and after 7 (LNCaP-16D), 9 (LNCaP-Abl) and 10 (LNCaP-Enz<sup>R</sup>) days, cell viability was determined using CellTiter-Blue and values were normalized over siControl. After incubating for 3 hours, viability was measured using a fluorescence reader (EnVision 2014).

251

252 The primary pooled siRNA and validation deconvolution screen were analysed in the following way. Using the CellTiter-Blue measurements of the positive and negative controls. 253 254 a z'factor was calculated per plate and plates with a z'factor < 0 were removed from the 255 dataset. The data was then normalized using Normalized percent inhibition<sup>41</sup>. After normalization, correlations between replicate plates were calculated and plates which did not 256 257 correlate well with the other replicate plates, were removed. Over the replicates a mean value 258 was calculated. Per condition a normalized distribution for mean values of the negative controls was approximated based on mean and SD value, and used to calculate for each 259 pooled siRNA a p-value, which was corrected for multiple testing using the Benjamini-260 261 Hochberg method. From the primary screen an initial selection was made of the siRNA pools that were a hit in at least two out of three cell lines, which produced a list of 11 hits. The 11 262 263 hits from the primary pooled subsequently selected for a screen were 264 deconvolution validation screen, in which four individual siRNAs were tested separately. All 265 targets with two individual siRNAs with among replicates a mean  $\leq 0.7$  and FDR  $\leq 0.1$ , where 266 considered validated hits. All calculation were done in R.

267

268 Expression levels per target gene in siRNA deconvolution experiments were assessed by 269 of qPCR analysis, specific primer-pairs ACTB (5'means using for 270 CCTGGCACCCAGCACAAT-3', 5'-GGGCCGGACTCGTCATACT-3'), FOXA1 (FW 5'-

271 GTGAAGATGGAAGGGCATGAA-3', REV 5'-CCTGAGTTCATGTTGCTGACC-3'), ASH2L (FW 5'-CTGACGTCTTGTATCACGTG-3', REV 5'-GCATCTTTGGGAGAACATTTG-3'), 272 GATA2 (FW 5'-GACAAGGACGGCGTCAAGTA-3', REV 5'-GGTGCCCATAGTAGCTAGGC-273 274 3') HDAC3 (FW 5'-ACGGTGTCCTTCCACAAATACG-3', 5'and REV 275 GGTGCTTGTAACTCTGGTCATC-3'). In brief, after siRNA transfection using the abovementioned protocol RNA was isolated using RNAGEM kit (MicroGEM), and guantified 276 bv Quant-iT<sup>™</sup> RiboGreen<sup>™</sup> RNA Assay Kit (Thermo Fisher Scientific), following 277 quantification cDNA was synthesized using the SuperScript™ III Reverse Transcriptase 278 279 system (Thermo Fisher Scientific, USA) with random hexamer primers according to the instructions provided by manufacturers. Quantitative PCR (gPCR) was performed using the 280 281 SensiMix<sup>™</sup> SYBR Kit (Bioline, UK) according to the manufacturer's instructions on a 282 QuantStudio<sup>™</sup> 6 Flex System (Thermo Fisher Scientific, USA). All data was firstly normalized over ACTB expression, and then over the siControl values. For all primer pairs, 2 biological 283 replicates with 2 technical replicates each were analyzed. 284

285

#### 286 PDX in vitro studies

Subcutaneous tumors were harvested and dissociated using the Miltenyi gentleMACS system with a Human Tumor dissociation kit (Miltenyi Corp). Cells were seeded in clear bottom white -walled flat bottom 96-well plates (20,000 cells per well) in RPMI and 10% FBS. ENZA (MedChem Express) and vorinostat (MedChem Express) 10mM in DMSO and diluted with RPMI to indicated concentrations. Effects of the treatments were evaluated after 5 days using CellTiter-Glo (Promega).

293

#### 294 Drug synergy assessment

295 In a 384-well plate, 500 LNCaP or LNCaP-16D cells were seeded and treated with various concentrations of ENZA (MedChemExpress, Monmouth Junction NJ, USA) and vorinostat 296 (kindly provided by Rene Bernards, NKI). Five days later, the CellTiter Glo assay (Promega 297 298 Benelux BV, Leiden, Netherlands) was performed according to the manufacturer's 299 instruction. All the assays were performed in biological quadruplicates (n=4). All the conditions (single and combination) were normalized to non-treated condition (set at 100). 300 SvneravFinder 2.0<sup>42</sup> was used to evaluate and plot synergistic potential using highest-single 301 agent (HSA) synergy reference model. Response of the two cell lines to single agent 302 303 vorinostat was also investigated and plotted using the normalized viability in full media (FBS) 304 and area under the curve (AUC) method.

305

#### 306 Single-cell analyses

Single-cell RNA-seq (GSE168669) data was used to produce UMAP visualizations of LNCaP parental and LNCaP RES-B retaining cluster identities from Taavitsainen *et al.*<sup>32</sup> The genes proximal to the 657 non-responder H3K27ac sites were compiled into a gene set expression analysis to produce scores per cell with AddModuleScore function from Seurat (version 4.3.0). Previously identified single-cell clusters (clusters 0 to 12)<sup>32</sup> were used in the enrichment analysis to overlap genes proximal to the 657 non-responder H3K27ac sites.

313

#### 314 **Results**

#### 315 Phase II trial of AR-targeted therapy in patients with mCRPC

To identify novel epigenetic biomarkers, we conducted a single-arm, open-label, phase 2 study in patients with mCRPC treated with a new line of AR targeted therapy, being a subinvestigation of the CPCT-02 biopsy protocol (NCT01855477) (Figure 1A). Between September 2014 and April 2019, a total of 64 mCRPC patients were enrolled in the trial. Baseline characteristics are summarized in Supplementary Table 1, trial outcomes in Supplementary Table 2 and Supplementary Figure 1: Consort diagram, with in-depth description of relevant clinicopathological parameters and outcomes included in the supplementary clinical trial data section (Supplementary Data).

324

#### 325 Biopsy assessment and evaluable population for biomarker discovery

326 All 64 patients had a pre-treatment biopsy from a metastatic lesion. Biopsy sites from the whole population include bone (n=19; 29.7%), lymph-nodes (n=32; 50.0%) and visceral 327 328 organs (n=13; 20.3%) (Supplementary Table 1). A second biopsy (post-treatment) was taken 329 upon disease progression for 15 patients. Biopsies with  $\geq$ 30% tumor cells were further 330 processed for downstream molecular analyses (42 and 12 for pre- and post-treatment, 331 respectively) (Supplementary Figure 1: Consort diagram). We successfully generated ChIP-332 seg data for active promoter/enhancer histone modification H3K27ac —passing stringent QC requirements (See Methods) for 22 out of the 42 samples. Four (18.2%) of the pre-treatment 333 334 biopsies evaluable for biomarkers, were from bone metastases, while 13 (59.1%) were from lymph-node metastases and 5 (22.7%) from visceral metastases (Supplementary Table 1). 335 336 For 6 of 15 post-treatment biopsies, we obtained high guality H3K27ac ChIP-seg data. One (16.7%) of the post-treatment biopsies was from bone, 3 (50.0%) were from lymph-nodes 337 338 and 2 (33.3%) were from visceral organs. One patient had both pre- and post-treatment 339 biopsies resulting in 28 biopsy samples for further analyses from 27 unique patients. The 340 baseline characteristics and treatment outcomes of the 22 patients who donated an evaluable 341 pre-treatment biopsy and the 6 patients who donated an evaluable post-treatment biopsy, 342 are summarized in Supplementary Table 1 and Supplementary Table 2, respectively. There were no significant differences in baseline age, serum PSA, the treatment outcomes, duration 343 344 of treatment, PSA change from baseline, and Time to PSA Progression (TTPP) between the

345 patients who donated an evaluable pre- and/or post-treatment biopsy and the whole 346 population (Supplementary Table 1 and Supplementary Table 2). Additional clinical 347 information and methods can be found in Supplementary Information.

348

349 Prior to functional genomic downstream analyses, all patients were categorized for their overall response, which was a composite of three outcomes: (1)  $\geq$  50% PSA decrease from 350 351 baseline, (2) radiographic response (stable disease, partial response or complete response), 352 and (3) longer than median TTPP. Assessment was conservative; in case a patient could not 353 be evaluated on a particular outcome measure, it was considered as no response. All patients 354 were evaluable for this endpoint, except for one patient (1.6%) who could not be evaluated for any of the three outcomes (Supplementary Table 2). In the whole population, 23.4% of 355 356 patients scored on all three items (Response to ENZA), 37.5% of patients did not score on 357 any item (No response to ENZA) and the remaining 37.5% of patients had inconsistent responses on the three outcome measures listed above (Intermediate response to ENZA). 358 359 Of the 22 patients in the pre-treatment evaluable population, 6 (27.3%) patients had a 360 response, 8 (36.4%) patients had an intermediate response, and 8 (36.4%) patients had no 361 response to ENZA (Supplementary Table S2). Of the 6 patients in the post-treatment evaluable population, 2 patients had a response (33.3%), 2 patients had an intermediate 362 363 response (33.3%), 1 patient had no response (16.7%) to ENZA treatment, while 1 patient 364 was not evaluable (16.7%) (Supplementary Table S2). Based on the ChIP-seq QC 365 parameters and clinical assessment of our trial data, 28 biopsies (22 pre- and 6 posttreatment, from 27 unique patients) with high quality ChIP-seq data are available, roughly 366 367 equally sized response groups were formed, with 8 responders, 10 intermediate and 9 non-368 responders to treatment (one unknown) (Figure 1B).

#### 370 Genome-wide epigenetic profiling of mCRPC

Apart from H3K27ac ChIP-seq data, for which we successfully generated high-quality data 371 for 28 metastatic biopsy samples (see above), 10 FOXA1 ChIP-seq and 2 AR ChIP-seq 372 373 datasets were generated on these fine needle core biopsies (Figure 1B and Supplementary Figure 1: CONSORT diagram). As all these patients received prior ADT, the low circulating 374 testosterone levels may explain the relatively low success-rate of AR ChIP-seg (of which 375 376 chromatin binding is decreased following ADT) as compared to FOXA1. For peak numbers, read counts and other relevant ChIP-seq QC parameters, see Supplementary Table 3 and 377 378 Supplementary Figure 2A,B.

379

All H3K27ac ChIP-seq samples were highly correlated based on genome-wide patterns 380 381 (Figure 1B) indicating low inter-tumor heterogeneity, and robust technical reproducibility. As 382 expected, and in line with our previous study on multiple metastases from the same patient<sup>22</sup>, FOXA1 and AR profiles were intermingled in our unsupervised hierarchical analysis reflecting 383 384 the direct biological interplay between these two factors<sup>16,43</sup>. No correlation was observed 385 with metastatic site or treatment condition/status or clinical response in the clustering with all 386 factors (Figure 1B), nor on H3K27ac alone (Supplementary Figure 3A,B). As H3K27ac ChIPseg data represented the largest and most-complete dataset, we decided to first focus on 387 388 these samples. For H3K27ac profiles, we found comparably high-quality peaks across all 389 three response groups, as exemplified on single locus (Figure 1C) and genome-wide scale 390 (Figure 1D). Taken together, our data indicate the vast majority of H3K27ac sites are 391 overlapping across sample types, irrespectively of AR-targeted therapy response.

392

**393** Distinct H3K27ac profiles identify mCRPC tumors resistant to AR-targeted therapy

394 While the total universe of H3K27ac profiles did not differ between response groups of 395 patients, possible subsets of regions may still exist that stratify patients on outcome. To ensure that subtle differences in cut-offs and definitions of treatment response would not 396 397 affect data interpretation, we performed supervised differential binding analysis<sup>44</sup> with the 398 H3K27ac data in the most extreme treatment response groups (responder and non-399 responder) (Figure 2A). In total, we observed 682 H3K27ac regions that significantly differed 400 between these response groups, with 657 sites selectively enriched in non-responder 401 patients and merely 25 sites found selectively enriched in responders (adj.p  $\leq$  0.05, logFC  $\geq$ 402 abs[2], Figure 2B). As expected for H3K27ac ChIP-seq, both sets of sites are predominantly found in distal intergenic regions (Supplementary Table 4). Differentially enriched peaks 403 404 between responders and non-responders were robust, as exemplified for three genomic loci 405 (Figure 2C), and guantified showing enriched signal in non-responders compared to 406 responders across all non-responder sites (Figure 2D).

407

408 To determine whether the 657 H3K27ac sites enriched in non-responders represent an acquired feature of mCRPC, or whether H3K27ac signal at these regions is already present 409 410 in the primary disease setting and associated with aggressiveness, we re-analyzed H3K27ac 411 ChIP-seq data from a matched case-control cohort of treatment naïve primary prostate cancer patients that we reported previously<sup>30</sup>. We observed no difference in H3K27ac signal 412 413 at these sites based on case/control status (Supplementary Figure 4A), nor on Gleason score (7 versus 9) (Supplementary Figure 4B) while typical signal for known primary-specific AR 414 binding sites was clearly present<sup>16</sup> (Supplementary Figure 4C). Further supporting the notion 415 416 that these regions are acquired in the treatment-resistance metastatic setting, we observed stronger signal in the non-responder metastatic samples (this study) compared with treatment 417 naïve metastasis samples and previously reported primary prostate cancer samples<sup>18</sup> as well 418

as healthy prostate tissue<sup>18</sup> (Supplementary Figure 4D). Together, these data suggest that
the resistance-associated H3K27ac sites represent an mCRPC-unique feature of resistance
to AR-targeted therapy. Collectively, our data indicate that a specific subset of H3K27ac sites
enables us to stratify mCRPC patients for an outcome to third generation AR inhibitor
treatment.

424

# 425 Resistance-associated H3K27ac profiles predict response to castration in mCRPC 426 patient-derived xenografts

427 H3K27ac profiling in clinical samples allowed us to stratify tumors from mCRPC patients on 428 response to AR-targeted therapeutics. To independently validate these findings and to 429 explore the potential for stratification beyond our own study, we next investigated an existing 430 H3K27ac ChIP-seq dataset that we previously reported for mCRPC PDX samples<sup>18</sup>. The 431 PDX models were generated from CRPC prostate cancer tumors, and represent metastatic samples from multiple metastatic sites, including adrenal glands, ascites, bladder, bone, 432 433 bowel, lymph-node and liver<sup>36</sup>. Originally, to determine the hormone-dependency of the PDX 434 tumor growth, PDX tumors were grown in testosterone proficient male mice, after which the 435 animals were either castrated or left intact (see overview in Figure 3A).

436

To evaluate whether the PDX tumors would classify according to the 657 non-responder H3K27ac sites, we plotted H3K27ac ChIP-seq data for these sites in 15 available PDX samples (Figure 3B and Figure 3C). Interestingly, 7 PDXs (45%) displayed strong H3K27ac signal at these regions, while the remaining 8 PDX samples (55%) displayed weak signal at these sites; with no significant global differences between these two groups of samples (Supplementary Figure 5). Integrating these cistromic data with the *in vivo* response-tocastration data showed that a strong H3K27ac signal is correlated with less tumor regression

444 upon castration of the animals (Figure 3D, raw data Supplementary Figure 6). In contrast, PDXs with weak H3K27ac signal at our clinically observed H3K27ac non-responder sites, 445 showed tumor regression upon animal castration. Importantly, using single-cell RNA-seq data 446 447 (scRNA-seq) from prostate cancer cell lines, we find genes associated with our clinically 448 observed H3K27ac non-responder sites as significantly enriched in a cell cluster that selectively appears in LNCaP-derived ENZA-resistant cells<sup>32</sup> (cluster 3) (Figure 3E). After 449 long-term treatment with ENZA, cluster 3 enriched mainly for LNCaP RES-B resistant cells 450 and only partially for RES-A cells. In fact, in LNCaP RES-B cells cluster 3 was expanded 451 452 compared to parental cells and also compared to RES-A, indicating that these cells drive 453 resistance-specific biology. In addition, average gene expression of genes associated with 454 H3K27ac non-responder sites was linked with cluster 3 expansion (Figure 3F). Interestingly, 455 scATAC-seq (single cell Assay for Transposase-Accessible Chromatin using sequencing) clusters identified previously to be associated with scRNA-seq cluster 3<sup>32</sup>, indicated no 456 selective enrichment of known transcription factors involved in treatment-mediated chromatin 457 458 reprogramming in prostate cancer. Together, these data illustrate that distinct H3K27ac 459 signals stratifying patients for response to AR blockade, and we validated the same profiles in mCRPC PDX models and at the single-cell level in models of ENZA resistance. 460

461

#### 462 Driver identification for resistance to AR inhibition in mCRPC

Using the combined datastreams of H3K27ac ChIP-seq and response-to-castration in PDX models, we successfully validated our 657 H3K27ac sites as indicative for unresponsiveness to hormonal intervention in mCRPC. As no selective transcription factor usage was enriched upon integrating scRNA-seq and scATAC-seq data, we conclude that possibly multiple factors -or proteins binding the genome without direct DNA recognition motif, drive resistance. Therefore, instead of TF motif analyses, we used GIGGLE; a genomics search engine that

469 queries previously-reported protein/chromatin occupancy datasets and ranks the significance of genomic loci shared between guery and a database of regions<sup>35</sup>. Specifically, we analyzed 470 an extensive database of ChIP-seq experiments from prostate tissue-derived cell lines and 471 prostate cancer cell lines<sup>34,45</sup> (Supplementary Table 5) to explore which DNA-associated 472 473 proteins bind at our defined non-responder H3K27ac sites (Figure 4A). This analysis 474 identified multiple factors previously reported to drive resistance to ENZA treatment or castration, including HNF4G<sup>46</sup>, NR3C1 (glucocorticoid receptor)<sup>47-49</sup> and FOXA1<sup>50</sup> 475 (Supplementary Table 5). To clinically validate the cell line-based GIGGLE enrichment data, 476 477 we next analyzed the FOXA1 ChIP-seq data from our mCRPC samples, separating the nonresponder (n=4) and responder (n=3) samples. These analyses revealed selective 478 479 enrichment of FOXA1 binding at the 657 non-responder H3K27ac sites in mCRPC samples 480 from non-responder patients, confirming the GIGGLE enrichment data (Figure 4B).

481

482 Next, we sought to explore the functional involvement of top-enriched factors (Supplementary 483 Table 5) in driving resistance to AR blockade (essential genes in our setting), by designing and performing a focused siRNA screen (4 pooled siRNAs per target (genes with median 484 485 GIGGLE combo enrichment score >20)) to target genes in two cell line models of castration resistance (LNCaP-Abl<sup>38</sup> and LNCaP-16D<sup>37</sup>) as well as a model of ENZA resistance (LNCaP-486 Enz<sup>R</sup>)<sup>40</sup> (Figure 4C). From the pooled siRNA experiments, eleven hits that significantly 487 488 diminished proliferation in at least two out of three cell lines (Figure 4D), relative to siControl 489 and were identified as top-enriched factors in the GIGGLE analysis, were selected for 490 deconvolution experiments in castration-resistant LNCaP-16D. Single siRNAs were tested 491 individually, in which decreased cell proliferation potential observed for at least 2 out of 4 siRNAs was considered a validated hit. These analyses identified factors previously 492 493 described as critical in driving resistance to both ENZA and castration in prostate cancer cell 494 lines: FOXA1<sup>50</sup> and GATA2<sup>51</sup> (Figure 4E, Supplementary Figure 7). Furthermore, two factors 495 previously reported to be associated with castration resistance, but not studied before for 496 their potential involvement in driving resistance to ENZA, were identified: HDAC3<sup>52</sup> and 497 ASH2L<sup>53</sup>. Collectively, these studies revealed potential drivers and possible drug targets to 498 treat castration-resistant prostate cancer.

499

# 500 Histone deacetylase (HDAC) inhibition synergizes with enzalutamide to block mCRPC 501 cell growth

502 Computational analyses and perturbation studies identified five factors of potential therapeutic interest. As transcription factors are considered challenging drug targets, we 503 504 focused on HDAC3 for further downstream studies. HDAC3 has previously been reported as 505 therapeutic target in castration-resistant prostate cancer<sup>52</sup>, but remains unexplored in the 506 ENZA-resistant setting. Highly selective HDAC3 inhibitors have been described but have not been explored for efficacy and tolerability in clinical trials<sup>54</sup>. Less specific HDAC inhibitors are 507 508 well characterized and clinically implicated in the treatment of several cancer types, including vorinostat in the treatment of cutaneous T-cell lymphoma<sup>55</sup>. Vorinostat has been previously 509 reported to block proliferation of prostate cancer cells<sup>56</sup> and to synergize with the AR-510 antagonist bicalutamide<sup>57</sup>. Consequently, HDAC inhibitors have the potential to overcome 511 resistance to established mCRPC treatments, including AR targeted drugs<sup>58</sup>. A significant 512 513 increase in sensitivity to HDAC inhibition was observed in castration-resistant LNCaP-16D cells relative to hormone-sensitive parental LNCaP cells (Supplementary Figure 8. 514 Importantly, in both LNCaP cells and LNCaP-16D cells, vorinostat synergized with ENZA 515 516 (Figure 4F, Supplementary Figure 9A). To further establish therapeutic proof-of-concept, subcutaneous PDX tumors were dissociated and treated ex vivo with increasing 517 518 concentrations of ENZA, vorinostat, or both, which allowed us to determine synergy (Figure 4G). In agreement with the cell line-based results, *ex vivo* drug response in mCRPC PDXs
confirmed synergistic interactions between vorinostat and ENZA (Figure 4G, Supplementary
Figure 9A, 9B).

522

In summary, by performing H3K27ac ChIP-seq analyses of metastatic lesions from mCRPC patients, we identified an epigenetics-based classification for response prediction to ARtargeted therapy which we successfully validated in mCRPC PDX mouse models. These analyses revealed drivers for resistance to AR-targeted therapeutics, and identified ENZA in combination with pan-HDAC inhibitor vorinostat as a novel synergistic and highly effective drug combination for the treatment of castration-resistant prostate cancer.

529

#### 530 Discussion

531 The clinical significance of the non-protein coding genome in prostate cancer is rapidly gaining attention. Recently, whole-genome sequencing of primary prostate cancer 532 specimens revealed enrichment of somatic mutations in AR chromatin binding sites<sup>59,60</sup>, a 533 subset of which functionally affected enhancer activity<sup>15</sup>. Not only in primary prostate cancer 534 535 but also in the mCRPC setting, non-coding somatic alterations have been reported, including amplification of enhancer elements that regulate expression of AR<sup>61,62</sup>, HOXB13<sup>18</sup> and 536 FOXA1<sup>18</sup>. In addition to somatic alterations in the primary DNA sequence or copy number, 537 538 modifications in epigenetic regulatory elements are proving crucial in prostate cancer development and progression. Furthermore, extensive epigenetic reprogramming and AR 539 enhancer plasticity have been related to tumorigenesis<sup>15,16</sup> and progression<sup>18</sup>, as well as 540 541 therapy resistance<sup>17</sup>. To date, deviations in enhancer regulation have not been extensively studied in castration-resistant disease and have not been explored in the context of a 542 543 controlled clinical trial. Here, we interrogated the epigenome in relation to AR-targeted 544 therapy response in mCRPC patients. Within our clinical cohort, epigenetic features revealed 545 a robust classification scheme predicting response to treatment. These findings additionally 546 revealed potential drivers of resistance as well as novel therapeutic drug combinations to 547 combat castration-resistant disease.

548

While ENZA improves outcome in patients with mCRPC<sup>12,13</sup>, a significant proportion of 549 mCRPC patients experience no response to AR-targeting treatment due to intrinsic 550 resistance mechanisms. Supporting the notion of a pre-existing treatment resistance patient 551 552 population, we found that H3K27ac profiles in mCRPC tumors remained unaltered following 553 ENZA treatment. These data suggest that these cancers were already resistant prior to drug 554 exposure, harboring epigenetic programs that support AR-independent cellular growth. In contrast, most previously described resistance mechanisms appeared to be treatment-555 induced, including AR mutations<sup>63-65</sup> and amplification<sup>40</sup>, GR upregulation<sup>47-49</sup> or enrichment 556 of HNF4G<sup>46</sup>. As the tumor samples we analyzed were already relapsed after prior therapies 557 and developed castration resistance, it is plausible that the induction of the abovementioned 558 559 resistance mechanisms occurred before our samples were taken. At the single-cell level, genes associated with our H3K27ac non-responder sites were significantly enriched in an 560 ENZA-resistance-associated cluster which expands after long-term treatment<sup>32</sup>, indicating 561 562 that the acetylated regions we have identified - and associated genes - are important in 563 driving therapeutic resistance in a subset of tumors. These results may jointly point towards the induction of divergent castration resistance mechanisms, which either sustain hormone-564 dependency (as in the case for our 'responder' population) or diverge towards complete 565 566 hormone-independence (our 'non-responder' population), in which other transcription factors 567 compensate for the lack of AR activity.

Apart from the hormone receptor family, transcription factors are generally considered challenging drug targets and potential other therapeutic strategies – such as epigenetic drugs – may prove of clinical benefit for these cases. Along these lines, for three of our hits: NKX3-1, FOXA1 and GATA2, specific inhibitors are yet to be developed. Recently, indirect small molecule inhibition of FOXA1 has been described, by means of targeting EZH2<sup>66</sup> and LSD1<sup>67</sup>, presenting a potential direct therapeutic avenue in this setting.

574 As HDAC3 expression has been shown to be critical for AR-driven transcriptional programs - both in hormone-sensitive and castration-resistant cell line models<sup>68</sup> – we chose to further 575 576 study the potential benefit of HDAC inhibition as a therapeutic strategy in mCRPC. Our data reveal that HDAC3 is also critically involved in resistance to AR-targeted therapeutics in the 577 mCRPC setting, and prove therapeutic proof-of-concept of a synergistic drug-drug interaction 578 between ENZA and the pan-HDAC inhibitor vorinostat, both in cell line models and mCRPC 579 580 PDX-derived explants. This drug has been clinically approved in the treatment of cutaneous 581 T cell lymphomas and also shown promise as a therapeutic strategy in advanced non-small cell lung cancer<sup>69</sup>. Although, vorinostat showed no activity as a single agent in mCRPC 582 583 patients, a phase 2 trial into the combination of the non-selective HDAC inhibitor panobinostat 584 and the AR targeted drug bicalutamide in 55 patients, showed promising results<sup>70,71</sup>. Common drug-related serious adverse events such as thromboembolic events associated 585 with vorinostat are of concern<sup>55</sup>, but may be avoided with the likely lower concentrations used 586 in a combination with ENZA. 587

588

589 Conclusions

All rights reserved. No reuse allowed without permission.

- 590 Based on our results, new clinical trials for testing vorinostat or other HDAC inhibitors in
- 591 conjunction with ENZA for mCRPC patients would be justified, since novel highly-effective
- 592 drug-drug combinations are urgently needed to combat this deadly disease.
- 593
- 594
- 595 **Declarations**
- 596 Ethical Approval and Consent to Participate

597 The trial was approved by the institutional review board of the Netherlands Cancer Institute, 598 written informed consent was signed by all participants enrolled in the study, and all research 599 was carried out in accordance with relevant guidelines and (inter-)national and ethical 600 standards. Within the General Data Protection Regulation, patients always had the 601 opportunity to object or actively consent to the (continued) use of their personal data and 602 biospecimens for research purposes.

- 603
- 604 Consent for Publication
- 605 All authors have read the manuscript and consent to publication.
- 606
- 607 Availability of Supporting Data

608 Raw ChIP-sequence data are deposited in the European Genome-Phenome Archive 609 (EGAS00001006161)

- 610
- 611 Competing Interests

612 WZ and AMB received research funding from Astellas Pharma for the work performed in this

- 613 manuscript. All other authors declare no competing interests.
- 614
- 615 Funding

This work is supported by Astellas Pharma Europe BV (WZ, AMB), The Prostate Cancer
Foundation (Challenge Award – MLF, MMP, WZ, TMS); The United States Department of
Defense (Idea Award, PC180367 – MLF, MMP, WZ); Oncode Institute (WZ), KWF Dutch
Cancer Society / Alpe d'HuZes (10084 – WZ, AMB and 7080 – AMB, MSvdH, LW), PNW
Prostate Cancer SPORE (P50CA097186, P01CA163227 – EC) and Craig Watjen Memorial
funds (EC); Academy of Finland (#349314 – AU) and Norwegian Cancer Society (#1980162018 – AU); S. H. and M.N. Academy of Finland (#312043, #310829).

### 624 Authors' Contributions

TMS, YZ, SP, WZ and AMB wrote the main manuscript text. TMS, YZ, SP, KS, HMN, LGB,
SH, YK, JK, SL, SS, CL, VvdN, JS, BM, GJ, GFJLvL, AU, RLB, EC, WZ and AMB prepared
and analyzed data for all figures and tables. All other authors reviewed the manuscript.

629 Acknowledgments

The authors gratefully acknowledge the patients and the families of patients who contributed to this study. We thank the NKI Genomics Core Facility, Core Facility Molecular Pathology and Biobanking, Research High Performance Computing Facility, Scientific Information Service for their excellent technical support and all group members from the Zwart, Bergman and Corey labs for highly constructive feedback and suggestions. The authors thank the A.U. Norwegian Cancer Society, Academy of Finland and Cancer Foundation Finland, S.H. and M.N. Academy of Finland and Sigrid Jusélius Foundation, Finnish Cancer Institute.

- 637
- 638 Authors' Information

\*Tesa M. Severson: Divisions of Oncogenomics and Molecular Carcinogenesis, The
 Netherlands Cancer Institute, Amsterdam, the Netherlands, Oncode Institute, Utrecht, the
 Netherlands

642

645

648

\*Yanyun Zhu: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the
 Netherlands, Oncode Institute, Utrecht, the Netherlands

\*Stefan Prekovic: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam,the Netherlands, Oncode Institute, Utrecht, the Netherlands

649 Karianne Schuurman: Division of Oncogenomics, The Netherlands Cancer Institute, 650 Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands

- 651652 Holly M. Nguyen: Department of Urology, University of Washington, Seattle, WA, USA
- 653654 Lisha G. Brown: Department of Urology, University of Washington, Seattle, WA, USA

Sini Hakkola: Prostate Cancer Research Center, Faculty of Medicine and Health Technology,
 Tampere University and Tays Cancer Centre, Tampere, Finland

658

655

Yongsoo Kim: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the
 Netherlands. Present working address: Department of Pathology, Cancer Center
 Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

662

665

Jeroen Kneppers: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam,the Netherlands, Oncode Institute, Utrecht, the Netherlands

- 666 Simon Linder: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the 667 Netherlands, Oncode Institute, Utrecht, the Netherlands
- 668

All rights reserved. No reuse allowed without permission.

Suzan Stelloo: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the
Netherlands. Present working address: Department of Molecular Biology, Faculty of Science,
Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University,
Nijmegen, 6525 GA Nijmegen, the Netherlands.

- 674 Cor Lieftink: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 675 Amsterdam, the Netherlands
- 676

673

- Michiel van der Heijden: Division of Molecular Carcinogenesis, The Netherlands Cancer
   Institute, Amsterdam, the Netherlands, Division of Medical Oncology, The Netherlands
   Cancer Institute, Amsterdam, the Netherlands
- 680
- Matti Nykter: Prostate Cancer Research Center, Faculty of Medicine and Health Technology,
   Tampere University and Tays Cancer Centre, Tampere, Finland
- 683
- 684 Vincent van der Noort: Department of Biometrics, The Netherlands Cancer Institute,685 Amsterdam, the Netherlands
- 686
- 687 Joyce Sanders: Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the688 Netherlands
- 689

- 690 Ben Morris: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 691 Amsterdam, the Netherlands
- 693 Guido Jenster: Department of Urology, Erasmus MC, Rotterdam, the Netherlands
- 694
   695 Geert JLH van Leenders: Department of Pathology, Erasmus MC Cancer Institute, University
   696 Medical Centre, Rotterdam, the Netherlands
- 697
   698 Mark Pomerantz: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard
   699 Medical School, Boston, MA, USA
  - 700
  - Matthew L. Freedman: Department of Medical Oncology, Dana-Farber Cancer Institute,
    Harvard Medical School, Boston, MA, USA, The Eli and Edythe L. Broad Institute,
    Cambridge, MA, USA
  - Roderick L. Beijersbergen: Division of Molecular Carcinogenesis, The Netherlands Cancer
    Institute, Amsterdam, the Netherlands
  - 707
  - Alfonso Urbanucci: Prostate Cancer Research Center, Faculty of Medicine and Health
     Technology, Tampere University and Tays Cancer Centre, Tampere, Finland, Department of
     Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
  - 711
  - Lodewyk Wessels: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute,
     Amsterdam, the Netherlands, Oncode Institute, Utrecht, the Netherlands, Department of
     EEMCS, Delft University of Technology, Delft, The Netherlands
  - 715
  - 716 Eva Corey: Department of Urology, University of Washington, Seattle, WA, USA
  - 717

All rights reserved. No reuse allowed without permission.

#Wilbert Zwart: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam,
the Netherlands, Oncode Institute, Utrecht, the Netherlands, Laboratory of Chemical Biology
and Institute for Complex Molecular Systems, Department of Biomedical Engineering,
Eindhoven University of Technology, Eindhoven, the Netherlands

#Andries M. Bergman: Division of Oncogenomics, The Netherlands Cancer Institute,
Amsterdam, the Netherlands, Division of Medical Oncology, The Netherlands Cancer
Institute, Amsterdam, the Netherlands

726

722

- 727 \*shared first authors
- 728 # corresponding authors: <u>w.zwart@nki.nl</u>, a.bergman@nki.nl
- 729
- 730
- 721
- 731
- 732
- 733
- 155
- 734
- 735
- . . .
- 736

#### 737 References

- 7381Ferlay, J. et al. Cancer statistics for the year 2020: An overview. Int J Cancer (2021).739https://doi.org:10.1002/ijc.33588
- 7402Mottet, N. *et al.* EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1:741Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol* **79**, 243-262 (2021).742<a href="https://doi.org/10.1016/j.eururo.2020.09.042">https://doi.org/10.1016/j.eururo.2020.09.042</a>
- 7433Freedland, S. J. *et al.* Risk of prostate cancer-specific mortality following biochemical recurrence after744radical prostatectomy. JAMA **294**, 433-439 (2005). <a href="https://doi.org:10.1001/jama.294.4.433">https://doi.org:10.1001/jama.294.4.433</a>
- 745 Kupelian, P. A., Mahadevan, A., Reddy, C. A., Reuther, A. M. & Klein, E. A. Use of different definitions 4 746 of biochemical failure after external beam radiotherapy changes conclusions about relative treatment 747 efficacy for localized prostate cancer. Urology **68**, 593-598 (2006). 748 https://doi.org:10.1016/j.urology.2006.03.075
- 7495Roehl, K. A., Han, M., Ramos, C. G., Antenor, J. A. & Catalona, W. J. Cancer progression and survival750rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term751results. J Urol 172, 910-914 (2004). <a href="https://doi.org:10.1097/01.ju.0000134888.22332.bb">https://doi.org:10.1097/01.ju.0000134888.22332.bb</a>
- Harris, W. P., Mostaghel, E. A., Nelson, P. S. & Montgomery, B. Androgen deprivation therapy: progress
   in understanding mechanisms of resistance and optimizing androgen depletion. *Nat Clin Pract Urol* 6,
   76-85 (2009). <u>https://doi.org:10.1038/ncpuro1296</u>
- 7557van Royen, M. E. *et al.* Compartmentalization of androgen receptor protein-protein interactions in756living cells. J Cell Biol 177, 63-72 (2007). <a href="https://doi.org:10.1083/jcb.200609178">https://doi.org:10.1083/jcb.200609178</a>
- 7578Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific758transcription. Cell 132, 958-970 (2008). <a href="https://doi.org:10.1016/j.cell.2008.01.018">https://doi.org:10.1016/j.cell.2008.01.018</a>

All rights reserved. No reuse allowed without permission.

- 7599Wang, Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent760prostate cancer. Cell 138, 245-256 (2009). <a href="https://doi.org:10.1016/j.cell.2009.04.056">https://doi.org:10.1016/j.cell.2009.04.056</a>
- 76110Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to genome-wide762predictions. Nat Rev Genet 15, 272-286 (2014). <a href="https://doi.org/10.1038/nrg3682">https://doi.org/10.1038/nrg3682</a>
- 76311Kim, T. K. & Shiekhattar, R. Architectural and Functional Commonalities between Enhancers and764Promoters. Cell 162, 948-959 (2015). <a href="https://doi.org/10.1016/j.cell.2015.08.008">https://doi.org/10.1016/j.cell.2015.08.008</a>
- 76512Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl766J Med **367**, 1187-1197 (2012). <a href="https://doi.org:10.1056/NEJMoa1207506">https://doi.org:10.1056/NEJMoa1207506</a>
- 76713Beer, T. M. *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med **371**,768424-433 (2014). <a href="https://doi.org/10.1056/NEJMoa1405095">https://doi.org/10.1056/NEJMoa1405095</a>
- Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. & Prekovic, S. Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. *Endocr Relat Cancer* 26, R31-R52 (2018).
   https://doi.org:10.1530/ERC-18-0289
- Mazrooei, P. *et al.* Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants
   on Master Transcription Regulators in Primary Prostate Tumors. *Cancer Cell* 36, 674-689 e676 (2019).
   https://doi.org:10.1016/j.ccell.2019.10.005
- 77516Pomerantz, M. M. *et al.* The androgen receptor cistrome is extensively reprogrammed in human776prostate tumorigenesis. *Nat Genet* **47**, 1346-1351 (2015). <a href="https://doi.org/10.1038/ng.3419">https://doi.org/10.1038/ng.3419</a>
- 77717Stelloo, S. *et al.* Androgen receptor profiling predicts prostate cancer outcome. *EMBO Mol Med* 7,7781450-1464 (2015). <a href="https://doi.org:10.15252/emmm.201505424">https://doi.org:10.15252/emmm.201505424</a>
- 77918Pomerantz, M. M. *et al.* Prostate cancer reactivates developmental epigenomic programs during<br/>metastatic progression. *Nat Genet* **52**, 790-799 (2020). <a href="https://doi.org/10.1038/s41588-020-0664-8">https://doi.org/10.1038/s41588-020-0664-8</a>
- 78119Scher, H. I. *et al.* Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated782Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol* **34**, 1402-7831418 (2016). <a href="https://doi.org:10.1200/JCO.2015.64.2702">https://doi.org:10.1200/JCO.2015.64.2702</a>
- Schwartz, L. H. *et al.* RECIST 1.1-Update and clarification: From the RECIST committee. *Eur J Cancer* 62, 132-137 (2016). <u>https://doi.org:10.1016/j.ejca.2016.03.081</u>
- 78621Singh, A. A. *et al.* Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.787*Life Sci Alliance* **2**, e201800115 (2019). <a href="https://doi.org:10.26508/lsa.201800115">https://doi.org:10.26508/lsa.201800115</a>
- 78822Severson, T. M. *et al.* Epigenetic and transcriptional analysis reveals a core transcriptional program789conserved in clonal prostate cancer metastases. *Mol Oncol* **15**, 1942-1955 (2021).790<u>https://doi.org:10.1002/1878-0261.12923</u>
- 79123Severson, T. M. *et al.* Characterizing steroid hormone receptor chromatin binding landscapes in male792and female breast cancer. *Nat Commun* **9**, 482 (2018). <a href="https://doi.org/10.1038/s41467-018-02856-2">https://doi.org/10.1038/s41467-018-02856-2</a>
- 79324Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079 (2009).794<a href="https://doi.org:10.1093/bioinformatics/btp352">https://doi.org:10.1093/bioinformatics/btp352</a>
- 795
   25
   Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9, R137 (2008).

   796
   https://doi.org:10.1186/gb-2008-9-9-r137
- 79726Marinov, G. K., Kundaje, A., Park, P. J. & Wold, B. J. Large-scale quality analysis of published ChIP-seq798data. *G3 (Bethesda)* **4**, 209-223 (2014). <a href="https://doi.org/10.1534/g3.113.008680">https://doi.org/10.1534/g3.113.008680</a>
- 79927Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic800Acids Res 44, W160-165 (2016). <a href="https://doi.org/10.1093/nar/gkw257">https://doi.org/10.1093/nar/gkw257</a>
- 80128Lopez-Delisle, L. *et al.* pyGenomeTracks: reproducible plots for multivariate genomic datasets.802Bioinformatics **37**, 422-423 (2021). <a href="https://doi.org:10.1093/bioinformatics/btaa692">https://doi.org:10.1093/bioinformatics/btaa692</a>
- 80329Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation,<br/>comparison and visualization. *Bioinformatics* **31**, 2382-2383 (2015).805https://doi.org:10.1093/bioinformatics/btv145
- 80630Stelloo, S. *et al.* Integrative epigenetic taxonomy of primary prostate cancer. *Nat Commun* 9, 4900807(2018). <a href="https://doi.org:10.1038/s41467-018-07270-2">https://doi.org:10.1038/s41467-018-07270-2</a>
- 80831Handle, F. *et al.* Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. *Sci Rep* 9,80913786 (2019). <a href="https://doi.org:10.1038/s41598-019-50220-1">https://doi.org:10.1038/s41598-019-50220-1</a>

All rights reserved. No reuse allowed without permission.

- 810 32 Taavitsainen, S. et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells 811 associated with prostate cancer relapse. Nat Commun 12, 5307 (2021). 812 https://doi.org:10.1038/s41467-021-25624-1
- 813
   33
   Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587 e3529 (2021).

   814
   https://doi.org:10.1016/j.cell.2021.04.048
- S15 34 Zheng, R. *et al.* Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis.
   S16 *Nucleic Acids Res* 47, D729-D735 (2019). <u>https://doi.org:10.1093/nar/gky1094</u>
- 817 35 Layer, R. M. *et al.* GIGGLE: a search engine for large-scale integrated genome analysis. *Nat Methods*818 15, 123-126 (2018). <u>https://doi.org:10.1038/nmeth.4556</u>
- 81936Nguyen, H. M. et al. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular820Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.821Prostate 77, 654-671 (2017). https://doi.org:10.1002/pros.23313
- 82237Bishop, J. L. *et al.* The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed823Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov 7, 54-71 (2017).824https://doi.org:10.1158/2159-8290.CD-15-1263
- 82538Culig, Z. et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated826with prostate tumour progression in a new model system. Br J Cancer 81, 242-251 (1999).827https://doi.org:10.1038/sj.bjc.6690684
- 82839Kim, S. et al. PEG10 is associated with treatment-induced neuroendocrine prostate cancer. J Mol829Endocrinol 63, 39-49 (2019). <a href="https://doi.org:10.1530/JME-18-0226">https://doi.org:10.1530/JME-18-0226</a>
- 83040Kregel, S. et al. Acquired resistance to the second-generation androgen receptor antagonist831enzalutamide in castration-resistant prostate cancer. Oncotarget 7, 26259-26274 (2016).832https://doi.org:10.18632/oncotarget.8456
- Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput
  screening data analysis. *Nat Biotechnol* 24, 167-175 (2006). <u>https://doi.org:10.1038/nbt1186</u>
- 83542Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination836synergies. Nucleic Acids Res 48, W488-W493 (2020). <a href="https://doi.org/10.1093/nar/gkaa216">https://doi.org/10.1093/nar/gkaa216</a>
- 83743Stelloo, S. et al. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex838involved in prostate tumorigenesis.Oncogene**37**, 313-322 (2018).839https://doi.org:10.1038/onc.2017.330
- 84044Ross-Innes, C. S. *et al.* Differential oestrogen receptor binding is associated with clinical outcome in841breast cancer. Nature **481**, 389-393 (2012). <a href="https://doi.org:10.1038/nature10730">https://doi.org:10.1038/nature10730</a>
- 84245Mei, S. *et al.* Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in<br/>human and mouse. *Nucleic Acids Res* 45, D658-D662 (2017). <a href="https://doi.org:10.1093/nar/gkw983">https://doi.org:10.1093/nar/gkw983</a>
- 84446Shukla, S. *et al.* Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer845MediatesCastrationResistance.CancerCell32,792-806e797(2017).846<a href="https://doi.org:10.1016/j.ccell.2017.10.008">https://doi.org:10.1016/j.ccell.2017.10.008</a>
- 84747Li, J. *et al.* Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide848resistant prostate cancer. *Elife* 6 (2017). <a href="https://doi.org:10.7554/eLife.20183">https://doi.org:10.7554/eLife.20183</a>
- 84948Shah, N. *et al.* Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives850antiandrogen resistance in prostate cancer. *Elife* 6 (2017). <a href="https://doi.org/10.7554/eLife.27861">https://doi.org/10.7554/eLife.27861</a>
- 85149Puhr, M. et al. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a852Target for Improved Antiandrogen Therapy. Clin Cancer Res 24, 927-938 (2018).853https://doi.org:10.1158/1078-0432.CCR-17-0989
- 85450Jones, D. *et al.* FOXA1 regulates androgen receptor variant activity in models of castrate-resistant855prostate cancer. *Oncotarget* 6, 29782-29794 (2015). <a href="https://doi.org/10.18632/oncotarget.4927">https://doi.org/10.18632/oncotarget.4927</a>
- Chaytor, L. *et al.* The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled
  by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer. *Mol Cancer Res* **17**, 1264-1278 (2019). <u>https://doi.org:10.1158/1541-7786.MCR-18-1231</u>
- 85952McLeod, A. B. *et al.* Validation of histone deacetylase 3 as a therapeutic target in castration-resistant860prostate cancer. *Prostate* **78**, 266-277 (2018). <a href="https://doi.org:10.1002/pros.23467">https://doi.org:10.1002/pros.23467</a>

All rights reserved. No reuse allowed without permission.

- 86153Malik, R. *et al.* Targeting the MLL complex in castration-resistant prostate cancer. *Nat Med* **21**, 344-862352 (2015). <a href="https://doi.org:10.1038/nm.3830">https://doi.org:10.1038/nm.3830</a>
- 863 54 Liu, J. et al. Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted 864 Benzamide Zinc Binding Group. ACS Med Chem Lett 11, 2476-2483 (2020). 865 https://doi.org:10.1021/acsmedchemlett.0c00462
- 86655Olsen, E. A. *et al.* Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or867treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25, 3109-3115 (2007).868https://doi.org:10.1200/JCO.2006.10.2434
- 86956Butler, L. M. *et al.* Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses870the growth of prostate cancer cells in vitro and in vivo. *Cancer Res* 60, 5165-5170 (2000).
- 87157Marrocco, D. L. *et al.* Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor872expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer873cell proliferation. *Mol Cancer Ther* 6, 51-60 (2007). <a href="https://doi.org/10.1158/1535-7163.MCT-06-0144">https://doi.org/10.1158/1535-7163.MCT-06-0144</a>
- Biersack, B., Nitzsche, B. & Hopfner, M. HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer. *Cancer Drug Resist* 5, 64-79 (2022).
  https://doi.org:10.20517/cdr.2021.105
- 87759Morova, T. *et al.* Androgen receptor-binding sites are highly mutated in prostate cancer. *Nat Commun*878**11**, 832 (2020). <a href="https://doi.org:10.1038/s41467-020-14644-y">https://doi.org:10.1038/s41467-020-14644-y</a>
- 87960Zhou, S. *et al.* Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate880cancer. Nat Commun 11, 441 (2020). <a href="https://doi.org/10.1038/s41467-020-14318-9">https://doi.org/10.1038/s41467-020-14318-9</a>
- 88161Takeda, D. Y. *et al.* A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver882inAdvancedProstateCancer.*Cell***174**, 422-432e413(2018).883<a href="https://doi.org:10.1016/j.cell.2018.05.037">https://doi.org:10.1016/j.cell.2018.05.037</a>
- 884 62 Quigley, D. A. *et al.* Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell*885 174, 758-769 e759 (2018). <u>https://doi.org:10.1016/j.cell.2018.06.039</u>
- 886 63 Prekovic, S. *et al.* The Effect of F877L and T878A Mutations on Androgen Receptor Response to
  887 Enzalutamide. *Mol Cancer Ther* 15, 1702-1712 (2016). <u>https://doi.org:10.1158/1535-7163.MCT-15-</u>
  888 0892
- Korpal, M. *et al.* An F876L mutation in androgen receptor confers genetic and phenotypic resistance
  to MDV3100 (enzalutamide). *Cancer Discov* 3, 1030-1043 (2013). <u>https://doi.org:10.1158/2159-</u>
  891 8290.CD-13-0142
- 89265Sun, C. *et al.* Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell893survival. Oncogene 25, 3905-3913 (2006). <a href="https://doi.org:10.1038/sj.onc.1209424">https://doi.org:10.1038/sj.onc.1209424</a>
- 89466Park, S. H. *et al.* Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin895complex in prostate cancer. *Sci Adv* 7 (2021). <a href="https://doi.org/10.1126/sciadv.abe2261">https://doi.org/10.1126/sciadv.abe2261</a>
- 89667Gao, S. *et al.* Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate897cancer. Nat Genet 52, 1011-1017 (2020). <a href="https://doi.org:10.1038/s41588-020-0681-7">https://doi.org:10.1038/s41588-020-0681-7</a>
- 898 68 Welsbie, D. S. et al. Histone deacetylases are required for androgen receptor function in hormone-899 sensitive and castrate-resistant prostate cancer. Cancer Res **69**, 958-966 (2009). 900 https://doi.org:10.1158/0008-5472.CAN-08-2216
- 90169Gray, J. E. *et al.* Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small902902Cell Lung Cancer. *Clin Cancer Res* **25**, 6623-6632 (2019). <a href="https://doi.org/10.1158/1078-0432.CCR-19-1305">https://doi.org/10.1158/1078-0432.CCR-19-1305</a>9031305
- 90470Bradley, D. *et al.* Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy905(National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the906Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2907Consortium. *Cancer* 115, 5541-5549 (2009). <a href="https://doi.org:10.1002/cncr.24597">https://doi.org:10.1002/cncr.24597</a>
- 90871Ferrari, A. C. *et al.* Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in<br/>Castration-Resistant Prostate Cancer. *Clin Cancer Res* 25, 52-63 (2019). <a href="https://doi.org:10.1158/1078-0432.CCR-18-1589">https://doi.org:10.1158/1078-0432.CCR-18-1589</a>
- 911

All rights reserved. No reuse allowed without permission.

- 912
- 913

#### 914 Figure Legends

#### 915 Figure 1: Clinical trial design and ChIP-seq data collection

- A. Setup of the clinical trial. Patients with mCRPC are enrolled in the study, and an
   imaging-guided biopsy is taken prior to onset of enzalutamide treatment. One patient
   in the study was treated with abiraterone.
- 919 B. Correlation heatmap of ChIP-seq data (50kb bins across the genome, Pearson 920 correlation) for H3K27ac, AR and FOXA1 among all mCRPC samples (n=40). Colors 921 bars indicate ChIP factors: AR (light blue), FOXA1 (light green) and H3K27ac (dark 922 green), tissue of sample origin: lymph-node (grey), visceral organ (yellow) and bone 923 (dark green), treatment: abiraterone (Abi), salmon)) and enzalutamide (ENZA), 924 brown)), condition of the sample: pre-treatment (purple) and post-treatment (orange), 925 and treatment response: non-responder (dark purple), responder (pink), intermediate 926 (blue) and unknown (black outline).
- 927 C. Snapshot of H3K27ac ChIP-seq (n=28) in different treatment response groups:
  928 responders (pink), non-responders (purple), unknown ((unk.), black outline) and
  929 intermediate (blue). The read counts (left) and genomic coordinates (bottom) are
  930 indicated.
- D. Principal Component Analysis using normalized read counts in all peaks in H3K27ac
   ChIP-seq data (n=73039) from all samples (n=28). Samples labeled according to
   responders (pink), non-responders (purple), intermediate (blue) or unknown (white).
- 934

Figure 2: Distinct H3K27ac profiles stratify mCRPC patients on response to AR
inhibition

937 A. Differentially enriched regions from H3K27ac ChIP-seq data visualized by volcano 938 plot (n=73039). Regions marked by blue dots were significant (DiffBind DESeg2 two-939 tailed adjusted p-value  $\leq 0.05$ , logFC  $\geq$  abs|2|) (n=848); all other regions are shown with hexbin density to avoid over-plotting (n=72191). Each data point density tile 940 941 (hexagon) represents density of data within the tile from low (light grey) to high (black). 942 B. Heatmap showing normalized read count of H3K27ac data in significantly differentially 943 bound regions (DiffBind DESeq2 two-tailed adjusted p-value  $\leq 0.05$ , logFC  $\geq$  abs[2]) (n=848) in responder (n=8) and non-responder samples (n=9). Colors bars indicate 944 945 tissue of sample origin: lymph-node (grey), visceral organ (yellow) and bone (dark green), treatment: abiraterone (Abi), salmon)) and enzalutamide (ENZA), brown)), 946 947 condition of the sample: pre-treatment (purple) and post-treatment (orange) and 948 treatment response: non-responder (dark purple) and responder (pink).

- C. Individual snapshot of H3K27ac enriched differently in 3 responder patients (pink) and
   3 non-responder patients (purple) as examples. The read counts and genomic
   coordinates are indicated (top right and bottom, respectively).
- D. Average H3K27ac read count profiles of all merged data for responder patients (pink, n=8) and all merged non-responder patients (purple, n=9) at the 657 non-responder enriched sites (±5 kb from the peak center). Shading indicates standard-error of the data.
- 956

#### 957 Figure 3: mCRPC PDX validations of resistance-associated H2K27ac regions

A. Overview of the PDX models setup. Prostate cancer samples from mCRPC patients were obtained and implanted into the mouse to establish PDXs. These PDXs were characterized previously with their response to castration by the change of tumor volume.

B. Heatmap depicting raw read counts of H3K27ac ChIP-seq signal from PDX samples
at the non-responder enriched 657 H3K27ac regions, identified from the mCRPC
patient samples (±5 kb from the peak center ).

- 965 C. Average H3K27ac read count profiles of all PDX merged data for samples with weak
  966 (grey, n=8) and strong (black, n=7) signal in the non-responder 657 H3K27ac regions.
  967 (±5 kb from the peak center). Shading indicates standard-error of the data.
- 968 D. Box plots depicting doubling time of PDX models estimated using exponential 969 (Malthusian) growth model (y-axis) by group (x-axis). The central mark indicates the median, and the bottom and top edges of the box indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles. 970 respectively. The maximum whisker lengths are specified as 1.5 times the interguartile 971 972 range. All individual values are depicted as circles colored by PDX model (strong 973 H3K27ac - Castration: n=57, strong H3K27ac - Control: n=45, weak H3K27ac -974 Castration: n=71, weak H3K27ac – Control: n=73). Table below indicates the p-values 975 obtained for one-way ANOVA followed by Tukey HSD test for all combinations.

E. Polar plot reporting the -10\*log<sub>10</sub>(p-values) (Fisher's exact test) of gene overlap
 enrichment tests between genes associated with H3K27ac non-responder regions and
 LNCaP scRNA-seq cluster marker genes. Color indicates strength of significance from
 low (pink) to high (red).

F. Uniform manifold approximation and projection (UMAP) visualization showing the
 average gene expression score of genes associated with H3K27ac non-responder
 regions in the parental LNCaP (left) and the ENZA-Resistant, RES-B (right) single cells.
 Original scRNA-seq clusters (0-12) are superimposed on each plot.

984

985 Figure 4: Characterization of the non-responder enriched H3K27ac sites reveals
986 drivers of resistance

A. Enrichment analysis to determine significant overlap of 657 H3K27ac non-responder
sites with publicly available ChIP-seq data for factors previously studied in prostate
cancer cell lines (n=863). Graph shows median enrichment score for each factor
(GIGGLE combo score, indicating low to high significant enrichment score (Fisher's
exact two-tailed test and odds-ratio)). Factors are ordered by highest score
(enrichment) in the dataset with text shown in those with median enrichment score >
100.

- B. Average FOXA1 read count profiles of merged data, at the 657 non-responder
   enriched H3K27ac sites (±5 kb from the peak center), comparing responders (pink,
   n=8) and non-responders (purple, n=9). Shading indicates standard-error of the data.
- 997 C. Setup of siRNA screen to identify factors critical of prostate cancer cell line viability,
  998 resistant to androgen ablation or enzalutamide treatment.
- 999D. Screen results for pooled siRNAs, showing decreased viability of prostate cancer cell1000line models LNCaP-Abl (left), LNCaP-EnzR (middle) and LNCaP-16D (right). Cell1001viability was determined by CellTiter-Blue, and data are normalized over siControl.1002Bars indicate mean values  $\pm$  SD (n≥2). Adjusted P values (padj) were determined by1003two-sided t-test with multiple testing correction (Benjamini-Hochberg method).1004Statistically significant conditions (padj <0.05) are shown in red.</td>
- E. siRNA deconvolution experiment, separately analyzing each individual siRNA for the 1006 11 remaining hits in LNCaP-16D cells on cell viability. Cell viability was determined 1007 by CellTiter-Blue and data are normalized over siControl. Bars indicate mean values 1008  $\pm$  SD (n≥3). Adjusted P values determined as above. Statistically significant conditions 1009 (padj <0.05) are shown in red.
- 1010 F. Enzalutamide-vorinostat drug synergy analyses for LNCaP (top) and LNCaP-16D 1011 (bottom) based on viability experiments performed after 5 days of treatment.

1012	Vorinostat and enzalutamide (ENZA) concentrations in nM on the x- and y-axis,
1013	respectively. Synergy determined using the HSA model (score >10 indicates synergy
1014	with regions of maximal synergy outlined in white). Graphs representative for 4
1015	biological replicates.
1016	G. (Left) Experimental setup of tumor explant studies. Tumor samples are removed from
1017	the animals, and exposed ex vivo to increasing concentrations of enzalutamide and
1018	vorinostat and assessed for viability. (Right) Drug synergy representation for mCRPC
1019	PDX explant LuCaP 23.1. Synergy determined using the HSA model (score > 10
1020	indicates synergy with regions of maximal synergy outlined in white).

1021

#### 1022 Supplemental information

- 1023 Supplemental File 1:
- 1024 Contains 9 Supplementary Figures and 4 Supplementary Tables
- 1025
- 1026 Supplemental File 2:
- 1027 Contains additional clinical trial information

medRxiv preprint doi; https://doi.org/10.1101/2023.02.24.23286403; this version posted February 24, 2023. The copyright holder for this Figure previous and consection of the second data of the second dat



Response non-responder responder intermediate unknown

## Figure 2: Differential binding analysis of H3K27ac data for response status



D

С

regions significantly enriched in





# Figure 3: mCRPC PDX and scRNA-seq validations of resistance-associated H3K27ac regions





Figure 4: Characterization of the non-responder enriched H3K27ac sites reveals drivers of resistance

Vorinostat (nM)